Suchergebnisse

Public relations is often considered a function of fund raising by arts institutions. This is particularly true in the United States, where the tax laws encourage both individual and corporate contributions to nonprofit institutions. Through a variety of techniques, public relations has helped arts institutions gain visibility for their programs and stimulate community and corporate interest in specific projects. In recent years there has been concern about the introduction of hype into the art world. There is little evidence that either the practice of public relations or the increasing financial support from corporations is creating an overpromoted environment in the arts. Public interest in blockbuster exhibitions and other special events has developed spontaneously. There is also no evidence that arts institutions are compromising their integrity in seeking support from business. Corporate support of the arts can help achieve marketing results or be aimed exclusively at helping the community. Whatever the motivations, they provide opportunities for business people to demonstrate leadership in our society. Public relations can play the important role of helping to find common ground on which both business and the arts can seek to achieve their objectives.

This book offers a series of authoritative reviews on pain in psychiatric disorders written by leading experts. They discuss the complex interplay between pain and psychiatric disorders such as anxiety, depression and borderline personality disorder, as well as neurosteroids, epigenetic mechanisms and TRPV1, with a strong focus on neurobiological mechanisms and current and future therapeutic targets. Special attention is given to the importance of inflammation and the immune system as a common substrate in both pain and psychiatric disorders. The state-of-the-art reviews present both preclinical and clinical research, providing the reader with sound knowledge that provides a basis for further research and clinical practice. Pain in Psychiatric Disorders is of special interest to psychiatrists, neurologists, neuroscientists, pharmacologists and other healthcare professionals treating pain in psychiatric patients, as well as research students with an interest in this field

This work aims to develop methodologies to print pinhole-free, vertically stacked heterostructures by sequential deposition of conductive graphene and dielectric h-BN nanosheet networks. We achieve this using a combination of inkjet printing and spray-coating to fabricate dielectric capacitors in a stacked graphene/BN/graphene arrangement. Impedance spectroscopy shows such heterostructures to act as series combinations of a capacitor and a resistor, with the expected dimensional dependence of the capacitance. The areal capacitance ranges from 0.24 to 1.1?nF/cm2 with an average series resistance of ?120?k?. The sprayed BN dielectrics are pinhole-free for thicknesses above 1.65??m. This development paves the way toward fabrication of all-printed, vertically integrated, multilayer devices. ; This work was primarily supported by the SFI-funded AMBER research centre (SFI/12/RC/2278) as part of the platform projects program. In addition, we acknowledge Science Foundation Ireland (11/PI/1087) and the European Research Council (SEMANTICS) for continuing support. We have also received funding from the European Union Seventh Framework Program under Grant Agreement No. 604391 Graphene Flagship

An often overlooked aspect of service delivery in business‐to‐business settings is the issue of service quality among internal organizational units. Yet, in practice many organizational departments are service providers primarily to customers within the organization. For example, management information systems, human resources, and purchasing departments all share an important function supporting other employees as they perform their jobs. Managers of those internal service functions are becoming more concerned with delivering high levels of service quality to their internal customers. This article explores the dimensionality of customer service quality as perceived by a set of internal customers of an organizational buying unit, and examines the potential for segmentation of internal customers. Managerial implications and recommendations are presented to aid organizations desiring to improve internal service quality.

Background: Dementia is caused by a variety of neurodegenerative diseases and is associated with a decline in memory and other cognitive abilities, while inflicting an enormous socioeconomic burden. The complexity of dementia and its associated comorbidities presents immense challenges for dementia research and care, particularly in clinical decision-making. Main body: Despite the lack of disease-modifying therapies, there is an increasing and urgent need to make timely and accurate clinical decisions in dementia diagnosis and prognosis to allow appropriate care and treatment. However, the dementia care pathway is currently suboptimal. We propose that through computational approaches, understanding of dementia aetiology could be improved, and dementia assessments could be more standardised, objective and efficient. In particular, we suggest that these will involve appropriate data infrastructure, the use of data-driven computational neurology approaches and the development of practical clinical decision support systems. We also discuss the technical, structural, economic, political and policy-making challenges that accompany such implementations. Conclusion: The data-driven era for dementia research has arrived with the potential to transform the healthcare system, creating a more efficient, transparent and personalised service for dementia.

BACKGROUND: Dementia is caused by a variety of neurodegenerative diseases and is associated with a decline in memory and other cognitive abilities, while inflicting an enormous socioeconomic burden. The complexity of dementia and its associated comorbidities presents immense challenges for dementia research and care, particularly in clinical decision-making. MAIN BODY: Despite the lack of disease-modifying therapies, there is an increasing and urgent need to make timely and accurate clinical decisions in dementia diagnosis and prognosis to allow appropriate care and treatment. However, the dementia care pathway is currently suboptimal. We propose that through computational approaches, understanding of dementia aetiology could be improved, and dementia assessments could be more standardised, objective and efficient. In particular, we suggest that these will involve appropriate data infrastructure, the use of data-driven computational neurology approaches and the development of practical clinical decision support systems. We also discuss the technical, structural, economic, political and policy-making challenges that accompany such implementations. CONCLUSION: The data-driven era for dementia research has arrived with the potential to transform the healthcare system, creating a more efficient, transparent and personalised service for dementia.

BackgroundThere is considerable public interest in whether Europe is facing an opioid crisis comparable to the one in the United States and the contribution of opioid prescriptions for pain to a potential opioid crisis.MethodsA task force of the European Pain Federation (EFIC) conducted a survey with its national chapter representatives on trends of opioid prescriptions and of drug-related emergency departments and substance use disorder treatment admissions and of deaths as proxies of opioid-related harms over the last 20 years.ResultsData from 25 European countries were received. In most European countries opioid prescriptions increased from 2004 to 2016. The levels of opioid consumption and their increase differed between countries. Some Eastern European countries still have a low opioid consumption. Opioids are mainly prescribed for acute pain and chronic noncancer pain in some Western and Northern European countries. There was a parallel increase in opioid prescriptions and some proxies of opioid-related harms in France, Finland and the Netherlands, but not in Germany, Spain and Norway. In United Kingdom, opioid overdose deaths, but not opioid prescriptions increased between 2016 and 2018. There are no robust data available on whether prescribed opioids for pain patients contributed to opioid-related harms.ConclusionsThere are marked differences between European countries in trends of opioid prescribing and of proxies for opioid-related harms. Europe as a whole is not facing an opioid crisis. Discussions on the potential harms of opioids should not obstruct their prescription for cancer pain and palliative care.SignificanceEurope as a whole is not facing an opioid crisis. Some Eastern European countries have limited access to opioid medicines. Discussions on the potential harms of opioid medicines for noncancer pain should not obstruct opioid therapy for cancer therapy and palliative care.

Background There is considerable public interest in whether Europe is facing an opioid crisis comparable to the one in the United States and the contribution of opioid prescriptions for pain to a potential opioid crisis. Methods A task force of the European Pain Federation (EFIC) conducted a survey with its national chapter representatives on trends of opioid prescriptions and of drug-related emergency departments and substance use disorder treatment admissions and of deaths as proxies of opioid-related harms over the last 20 years. Results Data from 25 European countries were received. In most European countries opioid prescriptions increased from 2004 to 2016. The levels of opioid consumption and their increase differed between countries. Some Eastern European countries still have a low opioid consumption. Opioids are mainly prescribed for acute pain and chronic noncancer pain in some Western and Northern European countries. There was a parallel increase in opioid prescriptions and some proxies of opioid-related harms in France, Finland and the Netherlands, but not in Germany, Spain and Norway. In United Kingdom, opioid overdose deaths, but not opioid prescriptions increased between 2016 and 2018. There are no robust data available on whether prescribed opioids for pain patients contributed to opioid-related harms. Conclusions There are marked differences between European countries in trends of opioid prescribing and of proxies for opioid-related harms. Europe as a whole is not facing an opioid crisis. Discussions on the potential harms of opioids should not obstruct their prescription for cancer pain and palliative care. Significance Europe as a whole is not facing an opioid crisis. Some Eastern European countries have limited access to opioid medicines. Discussions on the potential harms of opioid medicines for noncancer pain should not obstruct opioid therapy for cancer therapy and palliative care.